Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
All content for Beyond the Endpoint is the property of Duke Clinical Research Institute and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
Stepping Up: From Curiosity to Confidence — What to Know Before You Join a Trial
Beyond the Endpoint
24 minutes 41 seconds
6 months ago
Stepping Up: From Curiosity to Confidence — What to Know Before You Join a Trial
Why do people volunteer for clinical trials — and what should they know before doing so?
In this episode of Beyond The Endpoint, we explore common questions, reasons, and myths about clinical trial participation. Hosts Manesh Patel and Emily O’Brien talk with guest Krista Camuglia, a Research Practice Manager with the Duke Heart Center Clinical Research Unit, who brings unique insights thanks to her work on the frontlines of research coordination.
🎙️ Listen to "Part 1: Why Participate in Clinical Research?" https://dcri.org/blog/ep-7-stepping-why-participate-clinical-research
Beyond the Endpoint
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
